Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 6/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.40 |
| ▸ | BRS3 | P32247 | 3/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334773 | 0.97 | LTB4R2 (0.43) | LTB4R2AGTR1AGTR2BRS3MME | |
| SCHEMBL7343001 | 0.94 | LTB4R2 (0.41) | LTB4R2AGTR1AGTR2BRS3KDM4C | |
| SCHEMBL7345747 | 0.93 | AGTR1 (0.40) | LTB4R2AGTR1AGTR2BRS3MME | |
| SCHEMBL7334298 | 0.93 | LTB4R2 (0.41) | LTB4R2AGTR1AGTR2BRS3MME | |
| SCHEMBL7336093 | 0.91 | AGTR1 (0.42) | LTB4R2AGTR1AGTR2BRS3MME | |
| SCHEMBL7342225 | 0.90 | AGTR1 (0.42) | LTB4R2AGTR1AGTR2BRS3MME | |
| SCHEMBL9553732 | 0.89 | AGTR1 (0.51) | LTB4R2AGTR1AGTR2BRS3MME | |
| SCHEMBL7336207 | 0.89 | AGTR1 (0.49) | LTB4R2AGTR1AGTR2 | |
| SCHEMBL7336047 | 0.89 | AGTR1 (0.50) | LTB4R2AGTR1AGTR2 | |
| SCHEMBL9552538 | 0.88 | AGTR1 (0.51) | LTB4R2AGTR1AGTR2BRS3MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6090828-A | ARTHERIOSCLEROSIS | REITZ DAVID B (US) | 2000-07-18 | — | — | US | disclosed |
| US-5451593-A | Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5451591-A | Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5196537-A | Angiotensin/II/ antagonists; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-03-23 | — | — | US | disclosed |
| WO-1992016523-A1 | 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |